BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 22544017)

  • 21. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Targeting metabotropic glutamate receptors to develop novel antipsychotics].
    Chaki S; Yoshida S; Okuyama S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):207-13. PubMed ID: 21226317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques.
    Richy FF; Banerjee S; Brabant Y; Helmers S
    Epilepsy Behav; 2009 Oct; 16(2):240-5. PubMed ID: 19699156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: a pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies.
    Berkowitz RB; McCafferty F; Lutz C; Bazelmans D; Godfrey P; Meeves S; Liao Y; Georges G
    Clin Ther; 2006 Oct; 28(10):1658-69. PubMed ID: 17157121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
    Vollmer T; Blight AR; Henney HR
    Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy.
    Marek GJ
    Curr Pharm Des; 2015; 21(26):3788-96. PubMed ID: 26044978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies.
    Kim TE; Gu N; Yoon SH; Cho JY; Park KM; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Feb; 34(2):482-94. PubMed ID: 22284902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects.
    Castelli MC; Wong DF; Friedman K; Riley MG
    Clin Ther; 2011 Jul; 33(7):934-45. PubMed ID: 21722960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study.
    Delanty N; Jones J; Tonner F
    Epilepsia; 2012 Jan; 53(1):111-9. PubMed ID: 22050371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis.
    Hobl EL; Mader RM; Jilma B; Duhm B; Mustak M; Bröll H; Högger P; Erlacher L
    Clin Ther; 2012 May; 34(5):1195-203. PubMed ID: 22516039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al.
    Seeman P
    J Clin Psychopharmacol; 2012 Apr; 32(2):291-2; author reply 292-293. PubMed ID: 22388160
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.